The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Phoenix VA Health Care System
Study ID
NCT02403284
Phase
PHASE4
Status
Completed

Conditions

  • Insulin Resistance

Eligibility Criteria

Sex
ALL
Age
40 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Liraglutide — DRUG
    Subcutaneous injection by patient
  • Sugar Pill — DRUG
    Subcutaneous injection daily

Study Details

In this research study, investigators will test the effects of an approved medication for diabetes,Liraglutide, to reduce insulin resistance that develops from eating a diet high in saturated fats.

Key Dates

Start date
Mar 31, 2013
Status verified
Jul 2024
Primary completion
Apr 28, 2021
Completion
Nov 1, 2023

Study Design

Enrollment
97 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Liraglutide
    Liraglutide titration up to 1.8 mg/d over approximately 3 weeks
  • Placebo Comparator: Sugar pill
    matching placebo and titration

Primary Outcome Measure

Whole Body Insulin Sensitivity (insulin suppression test) [ Time Frame: 3 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Carl T. Hayden VA Medical HospitalPhoenixArizona85012-

Find similar trials in Phoenix, AZ

By research site
Carl T. Hayden VA Medical Hospital· Phoenix, AZ

Related Studies